This program is developing and testing a new inhaled antibiotic therapy for cystic fibrosis. This therapy is a combination of two existing approved drugs: the antibiotic tobramycin and another compound, calcium EDTA. When bacteria infect the lungs of people with CF, they can form structures called biofilms. Biofilms make bacteria more resistant to antibiotics. The compound calcium EDTA may help break down biofilms in the lungs, allowing antibiotics to fight bacteria more effectively.

Status

A Phase 1 study to test the safety of inhaled RSP-1502 is currently underway.

Sponsor

This program is sponsored by Respirion Pharmaceuticals and partially funded by the Cystic Fibrosis Foundation. It is being conducted through the Therapeutics Development Network.